论文部分内容阅读
随着对三阴性乳腺癌( TNBC)分子生物学特征的深入研究，越来越多的潜在治疗靶点及药物也逐渐应用于临床，如以olaparib、veliparib等为代表的DNA损伤修复阻断剂、表皮生长因子受体为靶点的单克隆抗体西妥昔单抗、抗血管生成抑制剂贝伐单抗等使TNBC获益。临床需继续开展肿瘤科与分子生物学等学科的交叉研究，并深入对已有研究成果的安全性和有效性进行验证，为TNBC的临床治疗提供新的希望。“,”With the in-depth study of the molecular biological characteristics of triple-negative breast cancer( TNBC) ,more and more potential therapeutic targets and drugs are also increasingly used in the clini-cal treatment. The olaparib,veliparib as the representative of DNA damage repair blockers,monoclonal anti-body cetuximab targeting epidermal growth factor receptor,and anti-angiogenesis inhibitor bevacizumab make TNBC beneficialOncology and molecular biology cross-disciplinary research should be continued in clinical, and the depth study of the safety and effectiveness of existing research should be done for validation,in order to provide new hope for the clinical treatment of TNBC.